Journal List > Korean J Gastroenterol > v.66(4) > 1007423

Lee and Im: Hyperuricemia as a Novel Risk Factor for Colorectal Adenomatous Polyp

Abstract

Article

Uric Acid Is a Risk Indicator for Metabolic Syndrome-Related Colorectal Adenoma: Results in a Korean Population Receiving Screening Colonoscopy

References

1. Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015; 47:127–141.
crossref
2. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64:1637–1649.
crossref
3. Schoen RE, Razzak A, Yu KJ, et al. Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer. Gastroenterology. 2015. DOI: doi:10.1053/j.gastro.2015.07.055. [Epub ahead of print].
4. Heitman SJ, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, Hemmelgarn BR. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and metaanalysis. Clin Gastroenterol Hepatol. 2009; 7:1272–1278.
crossref
5. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut. 1982; 23:835–842.
crossref
6. Pendergrass CJ, Edelstein DL, Hylind LM, et al. Occurrence of colorectal adenomas in younger adults: an epidemiologic necropsy study. Clin Gastroenterol Hepatol. 2008; 6:1011–1015.
crossref
7. Ben Q, An W, Jiang Y, et al. Body mass index increases risk for colorectal adenomas based on metaanalysis. Gastroenterology. 2012; 142:762–772.
crossref
8. Nam SY, Kim BC, Han KS, et al. Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol. 2010; 8:443–450. e1-e2.
crossref
9. Jorgensen B, Knudtson J. Stop cancer colon. Colorectal cancer screening–updated guidelines. S D Med. 2015. Spec No:82–87.
10. Wolin KY, Yan Y, Colditz GA. Physical activity and risk of colon adenoma: a metaanalysis. Br J Cancer. 2011; 104:882–885.
crossref
11. Liu CS, Hsu HS, Li CI, et al. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol. 2010; 10:51.
crossref
12. Stocks T, Lukanova A, Bjørge T, et al. Metabolic Syndrome Cancer Project Me-Can Group. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer. 2011; 117:2398–2407.
crossref
13. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010; 6:30–38.
crossref
14. Neogi T. Clinical practice. Gout. N Engl J Med. 2011; 364:443–452.
15. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension. 2005; 45:18–20.
crossref
16. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008; 359:1811–1821.
crossref
17. Wang YY, Lin SY, Lai WA, Liu PH, Sheu WH. Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. J Gastroenterol Hepatol. 2005; 20:1410–1415.
crossref
18. Kim HJ, Kim JE, Jung JH, et al. Uric acid is a risk indicator for metabolic syndrome-related colorectal adenoma: results in a Korean population receiving screening colonoscopy. Korean J Gastroenterol. 2015; 66:202–208.
crossref
19. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a metaanalysis. JAMA. 2006; 295:74–80.
20. Cai H, Zhang G, Wang Z, Luo Z, Zhou X. Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and metaanalysis. PLoS One. 2015; 10:e0126944.
crossref
21. Makar GA, Holmes JH, Yang YX. Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst. 2014; 106:djt374.
crossref
TOOLS
Similar articles